Harvard Bioscience INC 8-K filings

Harvard Bioscience (HBIO) presented an investor overview highlighting strategic debt refinancing, new executive leadership, and a focused strategy on translational science tools, aiming for enhanced financial flexibility and long-term growth.

Harvard Bioscience announced second quarter 2026 financial results, reporting an 11% year-over-year revenue increase to $22.7 million and raising its full-year revenue guidance.

Harvard Bioscience stockholders approved amendments to the company's Incentive Plan and Employee Stock Purchase Plan, increasing authorized shares.

Harvard Bioscience presented an investor overview detailing a strategic shift towards translational science tools, financial restructuring, and operational efficiencies aimed at driving future growth.

Harvard Bioscience reported first quarter 2026 results with revenues of $20.8 million, a slight decrease year-over-year, but saw gross margin expand to 59% and reaffirmed full-year guidance.

Harvard Bioscience details its strategic shift to translational science tools, highlighting strong FY25 adjusted financial performance and positive FY26 outlook.

Harvard Bioscience announced its fourth quarter and full-year 2025 financial results, alongside 2026 guidance and the permanent appointment of Mark Frost as CFO.

Harvard Bioscience stockholders approved a 1-for-10 reverse stock split to regain Nasdaq minimum bid price compliance.

Harvard Bioscience announced preliminary fourth quarter 2025 financial results, exceeding revenue guidance midpoint and achieving high-end gross margin, alongside a positive outlook for 2026 and a new long-term strategic focus.

Harvard Bioscience announces Project Viking, a strategic consolidation of manufacturing operations to improve efficiency and achieve significant cost savings by 2028.

Harvard Bioscience, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of voting shares, effective January 19, 2026.

Harvard Bioscience reports strong Q3 2025 operational progress, exceeding gross margin guidance and outlining strategic priorities for 2025 including debt refinancing.

Harvard Bioscience, Inc. announced a $40 million debt refinancing package with BroadOak Capital Partners, extending debt maturity and enhancing financial flexibility.

Harvard Bioscience, Inc. confirms it is on track to refinance or repay its existing credit agreement by the end of the fourth quarter of 2025.

Harvard Bioscience announced third quarter 2025 financial results, reporting improved net loss and Adjusted EBITDA, alongside plans to refinance or repay its debt in the fourth quarter.

Harvard Bioscience, Inc. received an additional 180 days, until March 30, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement, with its stock transferring to the Nasdaq Capital Market.

Harvard Bioscience, Inc. announced the appointment of Stephen DeNelsky, a veteran life sciences financing leader, to its Board of Directors, effective September 5, 2025.

Harvard Bioscience, Inc. has entered into a retention agreement with its Interim CFO, Mark Frost, offering a $100,000 bonus contingent on successful debt refinancing by March 2026.

Harvard Bioscience, Inc. received a waiver for debt defaults and amended its credit agreement, but faces substantial doubt about its ability to continue as a going concern without new capital.

Harvard Bioscience reports mixed second-quarter 2025 results with a revenue decline but improved cash flow from operations, while securing a credit agreement amendment to extend its refinancing deadline.

A leading life science technology company announces a planned CEO succession, new board appointments, and provides an update on its second-quarter revenue and gross margin expectations.

Harvard Bioscience, Inc. has filed an amended Form 8-K to disclose its non-compliance with Nasdaq's audit committee composition requirements following a director's resignation, and outlines its plan to regain compliance.

Harvard Bioscience, Inc. announced its non-compliance with Nasdaq's audit committee composition rule due to a recent director resignation, and plans to regain compliance within the allotted cure period.

Harvard Bioscience, Inc. announced the resignation of Alan Edrick from its board of directors, effective June 10, 2025, clarifying the departure was not due to any disagreement.

Harvard Bioscience, Inc. announced key board appointments, including John Duke as a new director and Katherine Eade as Lead Independent Director, alongside stockholder approval of an expanded incentive plan and other annual meeting proposals.

Harvard Bioscience announced its Q1 2025 financial results, revealing a revenue decrease compared to the previous year, alongside ongoing cost management initiatives and promising adoption of new organoid and telemetry systems.

Bertrand Loy, Lead Independent Director of Harvard Bioscience, will not seek re-election at the company's 2025 Annual Meeting.

Harvard Bioscience received a Nasdaq notice regarding minimum bid price non-compliance and announced the resignation of its CFO, Jennifer Cote, with Mark Frost appointed as Interim CFO.

Harvard Bioscience announces its Q4 and full-year 2024 financial results, showing a revenue decrease but improved net income in Q4, while navigating a difficult market environment.

Harvard Bioscience obtains a waiver for a covenant breach and adjusts its credit facility terms to address refinancing milestones and liquidity concerns.